Compare SONO & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SONO | ABCL |
|---|---|---|
| Founded | 2002 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Video Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | 2018 | 2020 |
| Metric | SONO | ABCL |
|---|---|---|
| Price | $15.77 | $5.83 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $19.67 | $8.40 |
| AVG Volume (30 Days) | 2.2M | ★ 5.0M |
| Earning Date | 05-04-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.91 |
| EPS | ★ 0.77 | N/A |
| Revenue | ★ $1,443,276,000.00 | $75,128,000.00 |
| Revenue This Year | $5.04 | N/A |
| Revenue Next Year | $6.53 | $21.85 |
| P/E Ratio | $19.04 | ★ N/A |
| Revenue Growth | N/A | ★ 160.56 |
| 52 Week Low | $10.12 | $2.75 |
| 52 Week High | $19.82 | $8.44 |
| Indicator | SONO | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 53.88 | 47.88 |
| Support Level | $12.77 | $3.40 |
| Resistance Level | $17.50 | $6.79 |
| Average True Range (ATR) | 1.01 | 0.43 |
| MACD | 0.07 | -0.07 |
| Stochastic Oscillator | 47.72 | 46.41 |
Sonos Inc is an audio company dedicated to elevating life through sound, offering a connected platform that brings together music, movies, stories, and conversations. Its portfolio includes home theater speakers, components, plug-in and portable speakers and headphones, known for exceptional sound, thoughtful design, ease of use and seamless access to audio content. Its partner products and other revenue categories include accessories for home integration, such as custom-designed stands, mounts, and shelving units, along with partnerships for architectural speakers and automotive sound systems, as well as licensing, advertising revenue, and subscription-based services. The company operates in the United States and other countries, with the majority of revenue coming from the United States.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.